Item 8.01 Other Events.

On May 19, 2022, Vertex Pharmaceuticals Incorporated ("Vertex") and Catalyst Biosciences, Inc. ("Seller") entered into and consummated an Asset Purchase Agreement, pursuant to which Vertex acquired Catalyst's complement portfolio and related intellectual property, including CB 2782-PEG (the "Transferred Assets").

In consideration for the purchase of the Transferred Assets, Vertex will pay to Seller a total of $60 million in cash. Vertex expects to record the $60 million purchase price in GAAP and non-GAAP operating expenses in the second quarter of 2022.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses